Incremental Data and Analyses from Ph 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs Presented
“These analyses support bringing bamzireotide expeditiously to patients, especially GEP-NETs patients whose target lesions all express SSTR2,” said Thijs Spoor, Perspective’s Chief Executive Officer. “We are incorporating these findings as a potential enrichment strategy into ongoing discussions with regulators on the design of a registration enabling study, and are targeting an end-of-Phase 2 meeting in the first quarter of 2027. FDA feedback and completion of the necessary clinical, regulatory, and operational activities are expected to enable initiation of the Phase 3 study in 2027.”
Share:
More News
“We are pleased with the outcome of our End-of-Phase 1 meeting with FDA and are confident in our development strategy for BH-30643 in EGFR C797S-positive NSCLC. Our planned Phase 2 trial, designed with registrational intent, builds on the encouraging clinical activity observed in SOLARA, where BH-30643 has demonstrated promising anti-tumor
Jai Rautela, Ph.D., MBA, Chief Executive Officer, Audax Biosciences, “Astellas shares our pioneering spirit in immuno-oncology making them an ideal partner for highly differentiated programs such as DAX-044. This partnership will expedite the planned phase 1 clinical evaluation of DAX-044 for the benefit of patients with various types of solid
“We are increasingly excited about the potential of zoci to provide an important new targeted therapeutic option for patients with multiple cancer types that commonly express DLL3, including epNECs,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. “We are pleased that results from
“FDA clearance of the IND for KT-300, a potential first-in-class TRIM7 inhibitor, is an important milestone for Kayak and brings our novel approach to RAS-driven cancers into the clinic,” said Josiah Hornblower, CEO of Kayak Therapeutics. “TRIM7 sits at a critical downstream node of the RTK–RAS signaling cascade, and its